Journal article
PET imaging of PARP expression using [18F]olaparib
- Abstract:
-
PARP inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization, genotoxic therapy evaluation, and target engagement imaging of novel PARP-targeting agents. Here, via the copper-mediated 18F-radiofluorination of aryl boronic esters, we accessed, for the first time, the 18F-radiolabeled isotopologue of the Food and...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 3.8MB)
-
(Version of record, pdf, 1.4MB)
-
- Publisher copy:
- 10.2967/jnumed.118.213223
Authors
Funding
Pancreatic Cancer UK
More from this funder
Bibliographic Details
- Publisher:
- Society of Nuclear Medicine Publisher's website
- Journal:
- Journal of Nuclear Medicine Journal website
- Volume:
- 60
- Issue:
- 4
- Pages:
- 504-510
- Publication date:
- 2018-11-02
- Acceptance date:
- 2018-08-22
- DOI:
- EISSN:
-
2159-662X
- ISSN:
-
0161-5505
Item Description
- Pubs id:
-
pubs:912131
- UUID:
-
uuid:0c81dcff-76c2-47c7-897d-9c05df3f9167
- Local pid:
- pubs:912131
- Source identifiers:
-
912131
- Deposit date:
- 2018-10-01
Terms of use
- Copyright holder:
- Society of Nuclear Medicine and Molecular Imaging
- Copyright date:
- 2018
- Notes:
-
© 2018 by the Society of Nuclear Medicine and Molecular Imaging, Inc. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users
to share and adapt with attribution, excluding materials credited to previous publications.
License: https://creativecommons.org/licenses/by/4.0/.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record